001053900 001__ 1053900
001053900 005__ 20260130163245.0
001053900 0247_ $$2doi$$a10.1093/neuonc/noaf201.0506
001053900 0247_ $$2ISSN$$a1522-8517
001053900 0247_ $$2ISSN$$a1523-5866
001053900 037__ $$aFZJ-2026-01598
001053900 082__ $$a610
001053900 1001_ $$0P:(DE-HGF)0$$aGeurts, Marjolein$$b0
001053900 1112_ $$a7th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies$$cHonolulu$$d2025-11-20 - 2025-11-23$$gSNO / WFNOS 2025$$wUSA
001053900 245__ $$aCTNI-09. VORASIDENIB AS MAINTENANCE TREATMENT AFTER FIRST-LINE CHEMORADIOTHERAPY IN IDH-MUTANT GRADE 2/3 ASTROCYTOMA: STUDY PROTOCOL FOR THE PLACEBO-CONTROLLED, TRIPLE-BLIND, RANDOMIZED PHASE III STUDY EORTC-2427 (VIGOR)
001053900 260__ $$c2025
001053900 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1769786867_27788
001053900 3367_ $$033$$2EndNote$$aConference Paper
001053900 3367_ $$2BibTeX$$aINPROCEEDINGS
001053900 3367_ $$2DRIVER$$aconferenceObject
001053900 3367_ $$2DataCite$$aOutput Types/Conference Abstract
001053900 3367_ $$2ORCID$$aOTHER
001053900 520__ $$aAbstractBACKGROUNDThe efficacy of vorasidenib as maintenance therapy after completion of standard of care remains unclear. The VIGOR trial will investigate the efficacy of adding vorasidenib as maintenance therapy after completion of standard radiochemotherapy in patients with astrocytoma, IDH-mutant, WHO grade 2 or 3.MATERIAL AND METHODSVIGOR is a comparative, randomized (1:1), triple-blinded, multicentre phase III superiority trial. A total of 468 adult patients with an astrocytoma, IDH-mutant, WHO grade 2 or 3, at least one prior neurosurgery, who were in need for radiochemotherapy and completed standard of care radiotherapy followed by chemotherapy will be randomized between placebo or vorasidenib monotherapy 40 mg once daily until disease progression, unacceptable toxicity, or withdrawal of patient consent for up to 5 years. The primary objective is to demonstrate that vorasidenib maintenance therapy improves locally assessed PFS from enrolment compared to placebo. Primary endpoint is PFS from randomization, patients are randomized upon completion of the adjuvant chemotherapy. Secondary endpoints include PFS from start of radiotherapy, overall survival, time to next intervention, toxicity, health related quality of life, neurological symptoms and neurocognitive function. Translational research including tissue samples, liquid biopsies, and neuroimaging data is planned. Patients will be enrolled in 10 European countries (European Organisation for Research and Treatment of Cancer (EORTC) sites), Australia (Cooperative Trials Group for Neuro-Oncology (COGNO) sites) and Canada (Canadian Cancer Trials Group (CCTG) sites). Trial activation is planned for December 2025. The inclusion duration is 3 years, total study duration is approximately 130 months (10.8 years).CONCLUSIONVIGOR (EORTC-2427-BTG) will investigate the efficacy and safety of adding maintenance vorasidenib after completion of radiochemotherapy in patients with newly diagnosed astrocytoma, IDH-mutant, WHO grade 2 or 3. If the trial is positive, this has the potential to become a new standard of care.CLINICAL TRIAL REGISTRATION2024-519404-27-00 (EudraCT-number).FUNDINGServier.
001053900 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001053900 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001053900 7001_ $$0P:(DE-HGF)0$$aLeRhun, Emilie$$b1
001053900 7001_ $$0P:(DE-HGF)0$$aMinniti, Giuseppe$$b2
001053900 7001_ $$0P:(DE-HGF)0$$aPadovan, Marta$$b3
001053900 7001_ $$0P:(DE-HGF)0$$aDuerinck, Johnny$$b4
001053900 7001_ $$0P:(DE-HGF)0$$aFranceschi, Enrico$$b5
001053900 7001_ $$0P:(DE-HGF)0$$aTouat, Mehdi$$b6
001053900 7001_ $$0P:(DE-HGF)0$$aPace, Andrea$$b7
001053900 7001_ $$0P:(DE-HGF)0$$aSahm, Felix$$b8
001053900 7001_ $$0P:(DE-HGF)0$$aFurtner, Julia$$b9
001053900 7001_ $$0P:(DE-HGF)0$$aAlbert, Nathalie$$b10
001053900 7001_ $$0P:(DE-HGF)0$$aLohman, Philipp$$b11
001053900 7001_ $$0P:(DE-HGF)0$$avan Zandvoort, Martine$$b12
001053900 7001_ $$0P:(DE-HGF)0$$aQuoilin, Caroline$$b13
001053900 7001_ $$0P:(DE-HGF)0$$aDaumer, Corinne$$b14
001053900 7001_ $$0P:(DE-HGF)0$$aKoh, Eng-Siew$$b15
001053900 7001_ $$0P:(DE-HGF)0$$aPitz, Marshall$$b16
001053900 7001_ $$0P:(DE-HGF)0$$aGorlia, Thierry$$b17
001053900 7001_ $$0P:(DE-HGF)0$$aWeller, Michael$$b18
001053900 7001_ $$0P:(DE-HGF)0$$avan den Bent, Martin$$b19
001053900 7001_ $$0P:(DE-HGF)0$$aPreusser, Matthias$$b20
001053900 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noaf201.0506$$gVol. 27, no. Supplement_5, p. v126 - v126$$x1523-5866$$y2025
001053900 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-HGF)0$$aForschungszentrum Jülich$$b11$$kFZJ
001053900 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a INM-4$$b11
001053900 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001053900 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-11$$wger
001053900 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
001053900 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
001053900 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
001053900 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
001053900 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
001053900 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-11
001053900 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
001053900 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
001053900 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2024-12-11
001053900 920__ $$lyes
001053900 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x0
001053900 980__ $$aabstract
001053900 980__ $$aEDITORS
001053900 980__ $$aVDBINPRINT
001053900 980__ $$aI:(DE-Juel1)INM-4-20090406
001053900 980__ $$aUNRESTRICTED